Therapeutic Classification: hormones, antidiabetics
Pharmacologic Classification: pancreatics, glucagon like peptide 1 glp 1 receptor agonists
Insulin Glargine
Absorption: Provides slower prolonged absorption and a relatively constant concentrations over 24 hr.
Distribution: Identical to endogenous insulin.
Half-Life: 56 min (prolonged in diabetic patients; biological half-life is longer).
Lixisenatide
Absorption: Bioavailability following SUBQ injection unknown.
Distribution: Extensively distributed to tissues.
Half-Life: 3 hr
Contraindicated in:
Use Cautiously in:
CV: peripheral edema
Derm: erythema, pruritus
Endo: hypoglycemia
F and E: hypokalemia
GI: nausea, vomiting, ↓appetite, abdominal distention, abdominal pain, cholecystitis, cholelithiasis, constipation, diarrhea, dyspepsia, flatulence, PANCREATITIS
GU: renal impairment (in association with nausea, vomiting, diarrhea, or dehydration)
Local: cutaneous amyloidosis, injection site reactions, lipodystrophy
Neuro: headache
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)
Drug-drug:
Lab Test Considerations:
Toxicity and Overdose: